Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

      14:52 - 15:02  |  Presenter: Michael Thomas

      • Abstract

      Loading...

  • +

    EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
    • +

      EP05.01-030 - CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315

      Presenter: Wilfried Ernst Erich Eberhardt

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-031 - Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

      Presenter: Fabienne Dorothea Lusky

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-126 - The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

      Presenter: Petros Christopoulos

      • Abstract

      Loading...

  • +

    EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
    • +

      EP16.01-019 - The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-small-Cell Lung Cancer

      Presenter: Sarah Richtmann

      • Abstract

      Loading...

  • +

    IS21 - Industry Symposium Sponsored by Daiichi Sankyo, Inc.: The Expanding Toolbox: Key Updates for ADCs in Lung Cancer

    • 13:30 - 14:30
    • 8/08/2022
    • Location: Strauss 3
    • Not for CME Credit
    • Type: Industry Symposium
    • Track: N/A
    • +

      Session Moderator

      13:30 - 13:30  |  Presenter: Michael Thomas

      • Abstract

      Loading...

    • +

      IS21.01 - Welcome and Introduction

      13:30 - 13:32  |  Presenter: Michael Thomas

      • Abstract

      Loading...

    • +

      IS21.02 - Emerging Targets for Therapeutic Strategies

      13:32 - 13:52  |  Presenter: Michael Thomas

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      OA15.05 - HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy

      14:52 - 15:02  |  Presenter: Benjamin Besse

      • Abstract

      Loading...